Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Evaluating sensitivity and specificity of the Biomeme Franklin™ three9 real-time PCR device and SARS-CoV-2 go-strips assay using clinical samples

Chet R. Voelker a,*, Anna R. Ochoa a, b, La’Quita Armstrong-Spenrath a, Lisa Lott d, Jennifer S. McDaniel a, c, August N. Blackburn d, Lauren E. Cornell b, c, Rachel Mahoney a, b, Susana N. Asin a

a Center for Advanced Molecular Detection, 59 Medical Wing, US Air Force, JBSA-Lackland, San Antonio, TX, United States
b General Dynamics Information Technology, Falls Church, VA, United States
c ABSS Solutions and Services, Upper Marlboro, MD, United States
d Science and Technology, 59 Medical Wing, US Air Force, JBSA-Lackland, San Antonio, TX, United States

ARTICLE INFO

Keywords:
COVID19
SARS-CoV-2
Diagnostic testing
Polymerase chain reaction
Austere environment

ABSTRACT

We evaluated the sensitivity and specificity of the Biomeme Franklin™ three9 Real-Time PCR Thermocycler and Biomeme SARS-CoV-2 Go-Strips in the detection of SARS-CoV-2. The Biomeme Franklin™ three9 platform is a portable, battery-operated system that could be used in remote settings. We assessed performance of the Biomeme SARS-CoV-2 detection system at a wide range of viral concentrations, examined cross-reactivity of the SARS-CoV-2 Go-Strips against several near-neighbor respiratory pathogens, and evaluated agreement against the BioFire® Respiratory Panel 2.1 in four clinical sample types. Our data indicate the Biomeme Go-Strips can reliably detect SARS-CoV-2 at a concentration of 4.2 × 10^3 copies/mL. No cross reactivity of the Go-Strips targets was detected against any of the tested near-neighbor respiratory pathogens. Cohen’s kappa statistics ranged from 0.68 to 0.92 between results from the Biomeme SARS-CoV-2 Go-Strips and the BioFire® Respiratory Panel 2.1 in all the different sample types. Compared to the BioFire® Respiratory Panel 2.1, the Biomeme SARS-CoV-2 Go-Strips demonstrated statistically significantly lower sensitivity in 3 out of 5 sample types. Overall, our study demonstrates the Biomeme Franklin™ three9 used with the SARS-CoV-2 Go-Strips is an effective system for the detection of SARS-CoV-2 that could potentially be used in a remote or austere environment.

1. Introduction

The World Health Organization declared Coronavirus Disease (COVID-19) a global pandemic on March 11th, 2020 [1]. Since then, the pandemic has disrupted the lives of people worldwide and placed a significant burden on health care systems. As of August 4, 2021, more than 200 million COVID-19 cases have been confirmed worldwide, including approximately 4.7 million deaths [2]. The unprecedented global impact of the COVID-19 pandemic highlights the need for rapid, reliable diagnostic tests for the detection of SARS-CoV-2 that can lead to early intervention, improved health outcomes, and reduced spread of the disease.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR) assays for the detection of viral RNA targets are the gold standard for SARS-CoV-2 diagnosis. Large healthcare facilities and laboratories in suburban and metropolitan areas have access to high-throughput, sample-to-answer RT-PCR platforms; however, more remote settings typically cannot access these technologies [3]. Rural areas, which on average, consist of older populations with higher rates of underlying health conditions lack access to testing due to limited resources and hospital closures as a result of the pandemic [4]. Military populations that operate in austere environments far removed from health care facilities also need access to adaptable molecular diagnostic approaches that enable early detection of SARS-CoV-2 or other highly contagious pathogens [5]. A cost-effective, easy-to-use application could address the capability gap faced by these communities.

The Biomeme Franklin™ three9 Real-Time PCR Thermocycler (Philadelphia, PA) system is a lightweight, portable, battery-powered qPCR device that can test biological samples without centrifugation, the use of frozen reagents, or a power source. Furthermore, the device is...
capable of multiplex detection of up to three targets in each sample, where nine samples can be tested in a single run. Real-time PCR results are displayed on a smartphone that is connected to the device via Bluetooth or a USB cable. The Biomeme SARS-CoV-2 Go-Strip assay is a qualitative test for the detection of SARS-CoV-2 viral RNA in nasopharyngeal, nasal, and oropharyngeal swab specimens, and nasopharyngeal washes or aspirates. Biomeme received Emergency Use Authorization for their SARS-CoV-2 Go-Strip assay from the FDA on August 11, 2020 [6].

The objective of this study was to evaluate the sensitivity and specificity of the Biomeme SARS-CoV-2 Go-Strips assay tested on the Biomeme Franklin™ three9 Real-Time PCR Thermocycler. We assessed the performance of the Biomeme SARS-CoV-2 Go-Strips assay utilizing Biomeme’s M1 extraction method at a range of viral concentrations and tested several upper respiratory near-neighbor pathogens in the SARS-CoV-2 Go-Strips to evaluate cross-reactivity. Finally, we evaluated sensitivity and specificity of the Biomeme SARS-CoV-2 Go-Strips by testing clinical upper respiratory samples using the BioFire® Respiratory Panel 2.1 (RP2.1; Salt Lake City, UT) as a reference standard and validated results from the Biomeme SARS-CoV-2 Go-Strips using Biomeme SARS-CoV-2 Go-Plates tested on the ThermoFisher Quantstudio™ 7 Flex Real-Time PCR System (Waltham, MA).

2. Materials and methods

2.1. Sensitivity testing of the Biomeme system

RNA was extracted and purified using Biomeme’s M1 Sample Prep Cartridge, a filtration-based manual extraction method where nucleic acid binds to a silica membrane inside of a piercing tool attached to a syringe. Sample is pumped through the membrane along the sealed cartridge chambers which contain lysin buffer, wash buffers, and an elution buffer. Following RNA extraction, Biomeme SARS-CoV-2 Go-Strips were used to detect SARS-CoV-2 in clinical samples. The Go-Strips are designed specifically for use with the Franklin™ three9 instrument. The assay reagents are lyophilized for the detection of SARS-CoV-2 gene targets including open reading frame 1ab (ORF1ab) and spike (S). The ORF1ab gene is FAM (Carboxyfluorescein)-labeled and the S protein is Texas RedX-labeled. All three targets are multiplexed primer/probes that are triplex reactions in one Go-Strip.

To evaluate the sensitivity of the Biomeme SARS-CoV-2 detection system, a dilution series was prepared. Six 1:10 serial dilutions of Heat Inactivated 2019 Novel Coronavirus (ATCC® VR-1986HK™; Manassas, VA) were prepared in RNase-free water from a stock concentration of 4.2 × 10³ genome copies/mL. Additional concentrations of 2.10 × 10³ and 1.05 × 10³ copies/mL were prepared to assess performance near the threshold of detection. ATCC® VR-1986HK™ is a preparation of strain 2019-nCoV/USA-WA1/2020 inactivated by heating to 65 °C of 30 min [7]. Each concentration was extracted and purified using the Biomeme M1 Sample Prep Cartridge Kit for RNA 2.0 according to manufacturer’s instructions for use [8]. RNA from the M1 extraction process was tested in triplicate by adding 20 ul of RNA to the lyophilized master mix contained in each Go-Strip well. Amplification and detection of ampli- con was performed in the Biomeme Franklin™ three9 Real-Time PCR device. Upon completion of RT-PCR, the Biomeme provides an interpreted result regarding which gene targets have been detected. No analysis of amplification plots is required to interpret results. Sample results with neither ORF1ab nor S detection but with RPC amplification are considered negative for SARS-CoV-2. Samples results with only ORF1ab detection are considered presumptive positive for SARS-CoV-2. Sample results with S or both S and ORF1ab amplification are considered positive for SARS-COV-2. Sample results with no targets detected are considered invalid and need to be retested.

2.2. Near-neighbor testing to assess cross-reactivity

Nineteen near-neighbor upper respiratory viral and bacterial pathogens were tested on the Biomeme SARS-CoV-2 Go-Strips assay. Genomic material for each near-neighbor pathogen was purchased from ATCC (Table 2). A single 1:10 dilution was prepared for each pathogen. Prepared dilutions were tested in the Biomeme SARS-CoV-2 Go-Strips assays in triplicate by adding 20 ul of dilution to the lyophilized master mix contained in each Go-Strip well. Amplification and detection of amplicon was performed on the Biomeme Franklin™ three9 Real-Time PCR device. Each near-neighbor pathogen was tested on the Bio Fire RP2.1 to confirm presence of the genomic material, with the exception of MERS-CoV and SARS-CoV-1 which are not included in the BioFire® RP2.1.

2.3. Clinical sample collection

Between November 6, 2020 and January 7, 2021, iSpecimen, Inc. (Lexington, MA) enrolled and consented individuals in California, New Jersey, and New York who tested positive or negative for SARS-CoV-2 by a CLIA approved PCR test at baseline, and collected four different sample types from under an approved Institutional Review Board (IRB) protocol. Additionally, the nasopharyngeal specimen type was collected in viral transport media and saline for each subject. The samples were shipped to the Center for Advanced Molecular Detection at Lackland Air Force Base in San Antonio, TX on dry ice for processing and testing. The study was determined to be EXEMPT from research regulation 32 CFR 219 regarding the protection of human subjects Category 4 [32 CFR 219.104(d)(4)], by the 59th Medical Wing (59 MDW), via the exempt review/determination process by the 59th MDW Institutional Review Board (IRB) Chairperson or designee, based on 32 CFR 219.104(d).

Samples collected were nasal swab (NS), nasopharyngeal swab in saline (NP-S), nasopharyngeal swab in viral transport media (NP-VTM), oropharyngeal swab (OP), and saliva. There were three cohort groups: Cohort #1 included 22 individuals (NS 21, NP-S 22, NP-VTM 17, OP 22, Saliva 17) who initially tested SARS-CoV-2 positive and were recollected within 0 to 14 days, cohort #2 included 37 individuals (NS 37, NP-S 36, NP-VTM 31, OP 37, Saliva 29) who initially tested SARS-CoV-2 positive and were recollected within 15 to 30 days, and cohort #3 included 94 individuals (NS 93, NP-S 87, NP-VTM 66, OP 93, Saliva 68) who tested negative for SARS-CoV-2 and were recollected within 30 days.

2.4. Performance comparison between the Biomeme SARS-CoV-2 go- strips and Biofire® RP2.1 SARS-CoV-2 component using clinical samples

Clinical iSpecimen samples were tested simultaneously on the Biomeme SARS-CoV-2 Go-Strips and BioFire® RP2.1. Each sample was extracted using the M1 Sample Prep Cartridge. Purified RNA from the M1 extraction procedure was amplified on the SARS-CoV-2 Go-Strips using the Biomeme Franklin™ three9 platform.

In parallel, amplification and pathogen detection of the iSpecimen clinical samples were performed on the RP2.1 via the BioFire® FilmArray® 2.0 according to manufacturer’s instructions for use [9]. The RP2.1 is a sample-to-answer, nested multiplexed PCR test that identifies targets from 22 different respiratory pathogens. RNA extraction and purification is performed within the RP2.1 assay pouch. The SARS-CoV-2 targets detected in the RP2.1 are spike protein (S) gene and membrane protein (M) gene. Results from the BioFire® RP2.1 (submitted manuscript) were used as the reference standard for calculating sensitivity and specificity on the Biomeme SARS-CoV-2 Go-Strips. The BioFire® RP2.1 was chosen as the reference standard because the assay was the first to receive De Novo marketing authorization from the FDA [10].
2.5. Validation testing of the Biomeme go-strip

To validate the results on the Go-Strips, the same purified RNA was amplified and detected on Biomeme SARS-CoV-2 Go-Plates using the ThermoFisher Quantstudio™ 7 Flex. Biomeme SARS-CoV-2 Go-Plates contain the same reagents as the SARS-CoV-2 Go-Strips but in a 96-well format.

2.6. Statistical analyses

Statistical analyses were performed using R version 4.0.3 and the R packages ‘epiR’ and ‘fmsb’. We used Cohen’s kappa statistics to estimate agreement and test the null hypothesis that agreement was random (i.e. kappa statistic equals zero) [11]. We used McNemar’s Chi-square test to test the null hypothesis that the platforms are equivalent in terms of sensitivity and specificity. We used probit regression to estimate the concentration for which 95% of tests would be positive for each of the two targets in the Biomeme Go-Strips. Confidence intervals for the 95% probit estimate were calculated using the inverse method in the ‘investr’ R package [12].

3. Results

3.1. Performance of Biomeme go-strips at low viral loads

Eight dilutions, ranging from 4.20 × 10^5 copies/mL to 420 copies/mL were tested to evaluate the performance of the Biomeme SARS-CoV-2 Go-Strip assay including M1 extraction at low viral concentrations (Table 1). At 4.20 × 10^5 copies/mL all replicates yield a positive result with the S gene detected in all replicates (average Ct of 36.7, SD: 0.9) and ORF1ab gene detected in five out of six replicates (Ct values of 37.0, 38.4, 38.5, 38.3, 37.5). SARS-CoV-2 was inconsistently detected in replicates at concentrations of 2.10 × 10^3 copies/mL and lower, with a significant drop off at 1.05 × 10^2 copies/mL. Probit regression indicates that the ORF1ab gene target would be positive in 95% of tests at a concentration of 6135.6 (95% CI = [3872.7, 75,916.8]) copies/mL and the S gene would be positive in 95% of tests at a concentration of 3349.8 (95% CI = [2415.8, 9942.5]) copies/mL.

3.2. Assessment of cross-reactivity between SARS-CoV-2 go-strip primers and near-neighbor pathogens

We tested genomic material from nineteen near-neighbor upper respiratory bacterial and viral pathogens, including six strains of other coronaviruses, for cross-reactivity with targets in the Biomeme SARS-CoV-2 Go-Strips assay (Table 2). For each near-neighbor pathogen, no targets were detected in the SARS-CoV-2 Go-Strips. As a positive control, all near-neighbor upper respiratory pathogens that are target on the Table 1

| Dilution Series of Heat-Inactivated SARS-CoV-2 Tested on Biomeme SARS-CoV-2 Go-Strips. |
|-------------------|-------------------|-------------------|
| Copies/mL         | Biomeme Go-Strips | Biomeme Go-Strips |
|                   | (Orf1ab)          | (S)              |
| 1 × 10^3          | 42,000,000        | 6/6 (24.2 ± 5.2) | 6/6 (23.7 ± 0.3) |
| 1 × 10^2          | 4,200,000         | 6/6 (28.0 ± 0.8) | 6/6 (26.8 ± 0.4) |
| 1 × 10^3          | 420,000           | 6/6 (29.8 ± 0.3) | 6/6 (29.3 ± 0.4) |
| 1 × 10^4          | 42,000            | 6/6 (33.2 ± 1.5) | 6/6 (32.8 ± 0.3) |
| 1 × 10^5          | 4200              | 5/6 (37.0, 38.4, 38.5, 38.3, 37.5) | 6/6 (36.7 ± 0.9) |
| 2 × 10^5          | 2100              | 2/6 (39.8, 37.3) | 4/6 (37.7, 37.6, 36.4, 36.7) |
| 4 × 10^5          | 1050              | 3/6 (38.0, 38.5, 37.9) | 0/6 (N/A) |
| 1 × 10^6          | 420               | 1/6 (38.1)       | 1/6 (36.3)       |

* Number of replicates that tested positive divided by total replicates tested.
* Mean Ct value ± standard deviation where all replicates tested positive or individual Ct values.

3.3. Agreement between Biomeme SARS-CoV-2 go-strips compared to BioFire® respiratory panel 2.1

We performed comparative diagnostic testing using four different clinical upper respiratory sample types (NS, NP-VTM, NP-S, OP, and saliva) to estimate positive percent agreement and negative percent agreement of the Biomeme SARS-CoV-2 Go-Strips when compared to the BioFire® RP 2.1. The clinical samples were collected from 1 to 28 days after an initial CLIA test, resulting in a range of viral loads from participants including samples with viral loads below the detection threshold for the BioFire RP2.1. Agreement between the Biomeme SARS-CoV-2 Go-Strips and the BioFire® RP 2.1 as measured by Cohen’s kappa coefficients were 0.92, 0.82, 0.79, 0.75, and 0.68 for NS, NP-VTM, NP-S, OP, and saliva respectively. There were statistically significant differences in the marginal frequencies as measured by McNemar test in three of the five sample types. Discordant results between the two platforms were overwhelming in Cohort #1 and Cohort #2 samples. Taken together this indicates that the Biomeme SARS-CoV-2 Go-Strips were not as sensitive in detecting SARS-CoV-2 as the BioFire® RP2.1. Counts for the comparative testing, positive percent agreement, and negative percent agreement are shown in Table 3.

3.4. Validation of Biomeme SARS-CoV-2 go-strips against Biomeme SARS-CoV-2 go-plates

We validated our results on the Biomeme SARS-CoV-2 Go-Strips by analyzing the same clinical samples on the Biomeme SARS-CoV-2 Go-Plates. There was a high concordance between the Go-Strip and Go-Plate results. Cohen’s kappa estimates ranged from 0.86 to 0.97 across specimen types. There were no statistically significant differences between the marginal frequencies, indicating that the Biomeme SARS-CoV-2 Go-Strips are equivalent in sensitivity to the Biomeme SARS-CoV-2 Go-Plates. Counts for the comparative testing, positive percent agreement, and negative percent agreement are shown in Table 4.

4. Discussion

As the Biomeme Franklin™ three9 Real-Time PCR device has been
assay can reliably detect SARS-CoV-2 at viral concentrations of 4.20 × 10^3 copies/mL and found no cross-reactivity with select near-neighbor upper respiratory tract pathogens. We also demonstrated agreement that is statistically significantly greater than chance between the Biomeme SARS-CoV-2 Go-Strips and BioFire® RP2.1 in all four clinical upper respiratory sample types tested including nasopharyngeal swab in VTM, the current gold standard sample used for RT-PCR detection of SARS-CoV-2. The Go-Strips showed reduced sensitivity as compared to the BioFire® RP2.1: however, these results were expected based on the differences in limit of detections reported by the manufacturers. BioFire® reports a limit of detection of 500 copies/mL for the RP2.1 and Biomeme reports a limit of detection of 1800 copies/mL [8, 9]. A high number of false negatives occurred in oropharyngeal swabs and saliva which we suspect is due to differences in viral load at the various collection sites [14, 15]. We speculate that the sensitivity of the Biomeme SARS-CoV-2 Go-Strip assay could be improved by lowering the volume of elution buffer in the M1 Sample Prep Cartridge. The cartridge contains approximately 800 μL of Biomeme Elution Buffer, where other extraction kits elute in approximately 1/16th of the volume [16]. The high elution volume in the M1 extraction process is necessary to ensure complete saturation of the binding column. The advantage of the M1 extraction process is that no centrifugation of external reagents, aside from external endogenous storage reagents, are required for RNA isolation and purification. Biomeme recently commercialized the next iteration of their mobile PCR device, the Franklin™ three9 ISP [17]. The new system has integrated sample processing built into the assay, where DNA/RNA is automatically extracted and purified from crude liquid samples and up to 27 PCR targets are detected in one sample. Eliminating the need for manual extraction using the M1 Sample Prep Cartridge could increase the sensitivity and performance of Biomeme assays.

This study should be interpreted in light of the follow limitations. It is possible that the near-neighbor pathogens could be positive in the Biomeme SARS-CoV-2 Go-Strips if the genomic concentrations were higher. Testing in this study was done in a controlled laboratory environment so it is possible that performance of the Biomeme system would be negatively impacted in an austere environment. Further studies should be conducted to evaluate the Biomeme system in field conditions. Lastly, the sample collection in this study lagged identification of CLIA testing. In positive samples many participants may have cleared the virus or have substantially lower viral loads than they would upon an initial presentation to a clinical setting for testing earlier in the course of illness. As a result, we speculate that there is an enrichment for samples around or below the limit of detection for the devices in this study. Thus, the positive percent agreement between the Biomeme SARS-CoV-2 Go-Strips and the BioFire® RP2.1 might be expected to be lower than if the study design compared clinic samples collected at the peak of viral illness. As a result, we speculate that there is an enrichment for samples around or below the limit of detection for the devices in this study. Thus, the positive percent agreement between the Biomeme SARS-CoV-2 Go-Strips and the BioFire® RP2.1 might be expected to be lower than if the study design compared clinic samples collected at the peak of viral shedding (earlier in the course of illness, closer to the typical presentation to the clinic for illness).

The Biomeme Franklin™ three9 and SARS-CoV-2 Go-Strip assay provide healthcare facilities, especially those in rural areas, and personnel in remote settings an affordable, easy-to-use molecular diagnostic platform that uses almost no space on the benchtop. The Biomeme system does not require specialized laboratory equipment or cold-storage reagents. Results for up to nine samples can be obtained in less than two hours, including the time for processing and extraction and minimal training is required to learn the procedure. Our evaluation of the sensitivity and specificity of the Biomeme SARS-CoV-2 Go-Strips supports results reported in the Food and Drug Administration to support Emergency Use Authorization. Future studies should be performed

### Table 3
Clinical Evaluation of Biomeme SARS-CoV-2 Go-Strips with BioFire® RP2.1 as Reference Standard.

| Sample Type | Detected BioFire/ Biomeme | Detected Go-Strip Only | Detected Go-Strip/ Go-Plate Only | Not Detected Go-Strip/ Go-Plate | Kappa | McNemar test p-value | PPA | NPA |
|-------------|--------------------------|------------------------|----------------------------------|--------------------------------|-------|----------------------|-----|-----|
| Nasal Swab | 20                       | 3                      | 0                                | 128                             | 0.919 [0.828,1.01], p < 6.77e-11 | 0.2482 | 0.87 [0.66, 1.00] | 1.00 [0.97, 1.00] |
| NP saline | 23                       | 8                      | 0                                | 114                             | 0.819 [0.697,0.941], p < 3.38e-11 | 0.0133 | 0.74 [0.55, 1.00] | 1.00 [0.97, 1.00] |
| NP VTM | 20                       | 7                      | 1                                | 86                             | 0.790 [0.649,0.930], p < 1.195e-9 | 0.0771 | 0.74 [0.54, 0.89] | 1.00 [0.94, 1.00] |
| Oral Swab | 21                       | 11                     | 0                                | 120                             | 0.751 [0.609,0.893], p < 2.2e-16 | 0.002569 | 0.66 [0.47, 0.81] | 1.00 [0.97, 1.00] |
| Saliva | 19                       | 12                     | 1                                | 82                             | 0.676 [0.510,0.842], p < 5.215e-8 | 0.005546 | 0.61 [0.42, 0.78] | 0.99 [0.93, 1.00] |

*Positive percent agreement.

Table 4
Comparison of Biomeme SARS-CoV-2 Go-Strips with Biomeme SARS-CoV-2 Go-Plate.

| Sample Type | Detected Go-Strip/ Go-Plate Only | Detected Go-Strip/ Go-Plate Only | Not Detected Go-Strip/ Go-Plate | Kappa | McNemar test p-value | PPA | NPA |
|-------------|---------------------------------|---------------------------------|---------------------------------|-------|----------------------|-----|-----|
| Nasal Swab | 19                              | 0                               | 1                               | 129 | 0.971 [0.913,1.03], p < 6.42e-11 | 1   | 1.00 [0.82, 1.00] | 1.00 [0.96, 1.00] |
| NP saline | 22                              | 0                               | 1                               | 122 | 0.974 [0.922,1.025], p < 1.376e-12 | 1   | 1.00 [0.85, 1.00] | 0.99 [0.96, 1.00] |
| NP VTM | 20                              | 0                               | 1                               | 67  | 0.968 [0.906,1.031], p < 6.258e-12 | 1   | 1.00 [0.83, 1.00] | 0.99 [0.92, 1.00] |
| Oral Swab | 19                              | 3                               | 2                               | 125 | 0.864 [0.747,0.981], p < 7.673e-10 | 1   | 0.86 [0.65, 0.97] | 0.99 [0.94, 1.00] |
| Saliva | 17                              | 0                               | 3                               | 91  | 0.903 [0.794,1.011], p < 1.77e-9 | 0.2482 | 1.00 [0.80, 1.00] | 0.97 [0.91, 0.99] |

*Positive percent agreement.

Negative percent agreement.
comparing the sensitivity and specificity of the Biomeme SAR-CoV-2 Go-Strips assay to other SARS-CoV-2 detection platforms to provide a better understanding of the performance of the system.

Disclaimer

The views expressed in this article are those of the authors and do not reflect the official views or policy of the Department of Defense or its Components. Authors are military service members, civilian employees, or contractors of the US Government. This work was prepared as part of their official duties. Title 17 USC §105 provides that ‘copyright protection under this title is not available for any work of the US Government.’ Title 17 USC §101 defines a US Government work as a work prepared by a military service member, employee, or contractor of the US Government as part of that person’s official duties.

The views of Biomeme are not necessarily the official views of, or endorsed by, the U.S. Government, the Department of Defense, or the Department of the Air Force. No Federal endorsement of Biomeme is intended.

CRediT authorship contribution statement

Chet R. Voelker: Conceptualization, Writing – original draft, Validation, Software, Writing – review & editing. Anna R. Ochoa: Validation, Software, Writing – review & editing. La’Quita Armstrong-Spenrath: Software, Writing – review & editing. Lisa Lott: Conceptualization, Writing – review & editing. Jennifer S. McDaniel: Writing – original draft, Writing – review & editing. August N. Blackburn: Writing – original draft, Formal analysis, Writing – review & editing. Lauren E. Cornell: Writing – original draft, Writing – review & editing. Rachel Mahoney: Software, Writing – review & editing. Susana N. Asin: Conceptualization, Validation, Writing – review & editing.

CRediT authorship contribution statement

Chet R. Voelker: Conceptualization, Writing – original draft, Validation, Software, Writing – review & editing. Anna R. Ochoa: Validation, Software, Writing – review & editing. La’Quita Armstrong-Spenrath: Software, Writing – review & editing. Lisa Lott: Conceptualization, Writing – review & editing. Jennifer S. McDaniel: Writing – review & editing. August N. Blackburn: Writing – original draft, Formal analysis, Writing – review & editing. Lauren E. Cornell: Writing – review & editing. Rachel Mahoney: Software, Writing – review & editing. Susana N. Asin: Conceptualization, Validation, Writing – review & editing.

Declaration of Competing Interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

This work was funded by the Defense Health Agency (DHA) CARES Act. We would like to thank the Biomeme Customer Service Team for their support. We especially thank Max Perelman, Jesse vanWestrienen, and Andrew Barnard for sharing knowledge and expertise on Biomeme products.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jcv.2021.105046.

References

[1] WHO Director-General’s opening Remarks At the Media Briefing On COVID-19 - 11 March 2020. 2020.
[2] WHO Coronavirus (COVID-19) Dashboard. 2021.
[3] H.M. Creager, B. Calvera, A. Schnaubelt, J.L. Cox, A.M. Cushman-Vokoun, S. M. Shirk, et al., Clinical evaluation of the BioFire(R) Respiratory Panel 2.1 and detection of SARS-CoV-2, J. Clin. Virol. 129 (2020), 104538.
[4] C. Henning-Smith, The Unique Impact of COVID-19 on Older Adults in Rural Areas, J. Aging Soc. Policy 32 (2020) 396–402.
[5] N.L. Michael, SARS-CoV-2 in the U.S. military - lessons for civil society, N. Engl. J. Med. 383 (2020) 2472–2473.
[6] FDA. Biomeme SARS-CoV-2 Real-Time RT-PCR test emergency use authorization. 2020. p. Food and Drug Administration Emergency Use Authorization of Biomeme, Inc. SARS-CoV-2 Real-Time PCR Test.
[7] ATCC. Heat-inactivated SARS-CoV-2, VR-1986HK™. 2020.
[8] Biomeme I. Biomeme SARS-CoV-2 Real-Time RT-PCR Test Instructions For Use. 2020. p. Biomeme SARS-CoV-2 Real-Time RT-PCR Test Instructions For Use.
[9] Diagnostics B. BioFire® respiratory panel 2.1 (RP2.1). 2020. p. BioFire® Respiratory Panel 2.1 (RP2.1) Instructions for Use.
[10] FDA. FDA permits marketing of First SARS-CoV-2 diagnostic test using traditional premarket review process. 2021. p. BioFire Respiratory Panel 2.1 is the First COVID-19 Diagnostic Test Granted Marketing Authorization Using the De Novo Review Pathway.
[11] J.R. Landis, G.G. Koch, The measurement of observer agreement for categorical data, Biometrics 33 (1977) 159–174.
[12] B. Greenwell, C. Schubert Kabban, investr: an R Package for Inverse Estimation, R. J 6 (2014) 90–100.
[13] S. Valtier, Development of assay panel for vector-borne disease research cooperative agreement D17AC00026. 59th Medical Wing, Office of the Chief Scientist, 2020, p. 19.
[14] J.G. Yoon, J. Yoon, J.Y. Song, S.Y. Yoon, C.S. Lim, H. Seong, et al., Clinical significance of a high SARS-CoV-2 viral load in the saliva, J. Korean Med. Sci. 35 (2020) e195.
[15] H. Wang, Q. Liu, J. Hu, M. Zhou, M.Q. Yu, K.Y. Li, et al., Nasopharyngeal swabs are more sensitive than oropharyngeal swabs for COVID-19 diagnosis and monitoring the SARS-CoV-2 load, Front Med. (Lausanne) 7 (2020) 334.
[16] C. Ambrogi, C. Prezioso, P. Checconi, D. Serrano, M. Casar, M. Capannari, et al., SARS-CoV-2: comparative analysis of different RNA extraction methods, J. Virol. Methods 287 (2021), 114008.
[17] Biomeme I. Franklin™ three9 ISP Real-Time PCR Thermocycler (EAU). 2020. p. Franklin™ three9 ISP Real-Time PCR Thermocycler Emergency Use Authorization Instructions for Use.